Prognostic Factors of Malignant Peritoneal Mesothelioma Experienced in Japanese Peritoneal Metastasis Center

The current standard of treatment for malignant peritoneal mesothelioma(MPM)is cytoreductive surgery(CRS)plus perioperative intraperitoneal or systemic chemotherapy(comprehensive treatment), The present study was performed to clarify the prognostic factors of PMP after comprehensive treatment. Among...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 46; no. 2; p. 395
Main Authors Yonemura, Yutaka, Canbay, Emel, Wakama, Satoshi, Sako, Shouzou, Ishibashi, Haruaki, Hirano, Masamitsu, Motoi, Shunsuke, Mizumoto, Akiyoshi, Takao, Nobuyuki, Ichinose, Masumi, Noguchi, Kousuke, Liu, Yang, Fushida, Sachio
Format Journal Article
LanguageEnglish
Published Japan 15.02.2019
Subjects
Chemotherapy, Adjuvant
Chemotherapy, Cancer, Regional Perfusion
Female
Humans
Hyperthermia, Induced
Male
Mesothelioma - diagnosis
Mesothelioma - therapy
Peritoneal Neoplasms - diagnosis
Peritoneal Neoplasms - therapy
Prognosis
Survival Rate
Online AccessGet more information

Cover

More Information
Summary:The current standard of treatment for malignant peritoneal mesothelioma(MPM)is cytoreductive surgery(CRS)plus perioperative intraperitoneal or systemic chemotherapy(comprehensive treatment), The present study was performed to clarify the prognostic factors of PMP after comprehensive treatment. Among 63 patients with MPM, male and female patients were 34 and 29. CRSwas performed in 47 patients and complete cytoreduction(CC-0) was performed in 14(22%)patients. Mean numbers of resected peritoneal sectors and organs were 5.2(1-13), and 2.9(0- 9), respectively. Hyperthermic intraperitoneal chemoperfusion(HIPEC)was performed in 27 patients. Grade 1/2, Grade 3, and Grade 4 complications were experienced in 5, 6, and 3 patients, respectively. One patient died of sepsis, and the mortality rate was 2.3%. Independent prognostic factors for favorable prognosis were performance of HIPEC, peritoneal cancer index (PCI)score C12, no distant metastasis and histologic epithelial type. Relative risk of no HIPEC, PCI score B13, presence of distant metastasis and non epithelial type were 7.69, 22.1, 3.6 and 3.9, respectively. Risk factors for death after comprehensive treatment were no HIPEC, PCI score B13, and non epithelial type. However, only 11(17%)patients showed PCI score C12. Accordingly, PCI score should be reducedC12 before CRSby neoadjuvant chemotherapy.
ISSN:0385-0684